ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Bicuspid Aortic Valve Stenosis: Favorable Early Outcomes With a Next-Generation Transcatheter Heart Valve in a Multicenter Study.

Monday, September 12, 2016

Submitted by

J. Rafael Sadaba

Source

Source Name: JACC: Cardiovascular Interventions

Source URL: http://www.ncbi.nlm.nih.gov/pubmed/27101906

Author(s)

Perlman GY, Blanke P, Dvir D, Pache G, Modine T, Barbanti M, Holy EW, Treede H, Ruile P, Neumann FJ, Gandolfo C, Saia F, Tamburino C, Mak G, Thompson C, Wood D, Leipsic J, Webb JG.

The presence of a bicuspid valve has been considered as a relative contraindication for transcatheter aortic valve implantation (TAVI). This a multicentre retrospective study of 51 patients with bicuspid aortic stenosis who had undergone TAVI using a next-generation transcatheter heart valve (Edwards SAPIEN 3). 30- day mortality was 3,9%. There were no cases of valve embolization, need for a second prosthesis or annular rupture. Post implantation ballooning was required in 7.8% of the patients. None of the patients had more than mild aortic regurgitation (AR). Mild AR was detected in 37% of the cases. Pacemaker implantation was required in 23,5% of the cases. In this group of patients with bicuspid aortic stenosis, implantation of a new-generation device was associated with minimal paravalvular regurgitation and good clinical outcomes, but a higher than usual need for pacemaker implantation.